Partner: Aleksandra Ciałkowska-Rysz

Medical University of Lodz (PL)

Recent publications
1.Rysz J., Franczyk B., Ławiński J., Olszewski R., Ciałkowska-Rysz A., Gluba-Brzózka A., The impact of CKD on uremic toxins and gut microbiota, TOXINS, ISSN: 2072-6651, DOI: 10.3390/toxins13040252, Vol.13, No.4, pp.252-1-23, 2021
Abstract:

Numerous studies have indicated that the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD) is strictly associated with the accumulation of toxic metabolites in blood and other metabolic compartments. This accumulation was suggested to be related to enhanced generation of toxins from the dysbiotic microbiome accompanied by their reduced elimination by impaired kidneys. Intestinal microbiota play a key role in the accumulation of uremic toxins due to the fact that numerous uremic solutes are generated in the process of protein fermentation by colonic microbiota. Some disease states, including CKD, are associated with the presence of dysbiosis, which can be defined as an “imbalanced intestinal microbial community with quantitative and qualitative changes in the composition and metabolic activities of the gut microbiota”. The results of studies have confirmed the altered composition and functions of gut microbial community in chronic kidney disease. In the course of CKD protein-bound uremic toxins, including indoxyl sulfate, p-cresyl glucuronide, p-cresyl sulfate and indole-3-acetic acid are progressively accumulated. The presence of chronic kidney disease may be accompanied by the development of intestinal inflammation and epithelial barrier impairment leading to hastened systemic translocation of bacterial-derived uremic toxins and consequent oxidative stress injury to the kidney, cardiovascular and endocrine systems. These findings offer new therapeutic possibilities for the management of uremia, inflammation and kidney disease progression and the prevention of adverse outcomes in CKD patients. It seems that dietary interventions comprising prebiotics, probiotics, and synbiotics could pose a promising strategy in the management of uremic toxins in CKD.

Keywords:

chronic kidney disease, uremic toxins, gut microbiota, cardiovascular risk

Affiliations:
Rysz J.-Medical University of Lodz (PL)
Franczyk B.-Medical University of Lodz (PL)
Ławiński J.-other affiliation
Olszewski R.-IPPT PAN
Ciałkowska-Rysz A.-Medical University of Lodz (PL)
Gluba-Brzózka A.-WAM Teaching Hospital (PL)
2.Gluba-Brzózka A., Franczyk B., Ciałkowska-Rysz A., Olszewski R., Rysz J., Impact of Vitamin D on the Cardiovascular System in Advanced Chronic Kidney Disease (CKD) and Dialysis Patients, Nutrients, ISSN: 2072-6643, DOI: 10.3390/nu10060709, Vol.10, No.709, pp.1-12, 2018
Abstract:

In patients suffering from chronic kidney disease (CKD), the prevalence of cardiovascular disease is much more common than in the general population. The role of vitamin D deficiency had been underestimated until a significant association was found between vitamin D therapy and survival benefit in haemodialysis patients. Vitamin D deficiency is present even in the early stages of chronic kidney disease. The results of experimental studies have revealed the relationship between vitamin D deficiency and impairment of cardiac contractile function, higher cardiac mass and increased myocardial collagen content. Experimental models propose that intermediate end points for the relationship between vitamin D deficiency and higher risk of cardiovascular disease comprise diminished left ventricular hypertrophy (LVH), enhanced left ventricular diastolic function, anddecreasedfrequencyofheartfailure. Multipleobservationalstudieshavedemonstrated an association between the use of active vitamin D therapy in patients on dialysis and with CKD and improved survival. However, there are also many studies indicating important adverse effects of such treatment. Therefore, large randomized trials are required to analyze whether supplementation of vitamin D may affect outcomes and whether it is safe to be used in CKD patient

Keywords:

vitamin D, chronic kidney disease, cardiovascular disease, mortality, vitamin D analogues, treatment

Affiliations:
Gluba-Brzózka A.-WAM Teaching Hospital (PL)
Franczyk B.-Medical University of Lodz (PL)
Ciałkowska-Rysz A.-Medical University of Lodz (PL)
Olszewski R.-IPPT PAN
Rysz J.-Medical University of Lodz (PL)